Is Increased Use of PGT-A Always Better? Experts Call for Evidence-Based Use of Mosaic Embryos
Choosing the Right PGT-A Platform: NUWA Fertility and Global Experts Unite to Advance IVF Success

TAIPEI, Aug. 6, 2025 /PRNewswire/ — Preimplantation Genetic Testing for Aneuploidy (PGT-A), a screening method used during IVF to assess embryo chromosomal health, has gained widespread adoption in reproductive medicine worldwide. Yet the accuracy of various PGT-A platforms and their true clinical value remain points of ongoing debate. To dive deeper into the science behind PGT-A and explore the latest validated technologies, NUWA Fertility partnered with the Institute of Biotechnology at National Taiwan University to host its annual Reproductive Medicine Forum on August 3. The event welcomed over 200 fertility professionals and representatives from more than 65 reproductive centers, drawing international experts from the U.S. and Japan for a day of lively discussion and data-driven insights.

New Global Research Questions Conventional Use of Mosaic Embryos

One of the forum’s most anticipated speakers, Dr. Chaim Jalas – CEO and Director of Research and Development at U.S.-based Juno Genetics – presented findings from two prospective studies spanning the U.S. and Europe, with a combined dataset of 15,000 embryo samples. The research showed that when PGT-A is performed using the most advanced, clinically validated platforms, mosaic embryos (those containing both normal and abnormal cells) do not necessarily need to be discarded. By accurately identifying and excluding only embryos with chromosomal abnormalities, clinics can improve live birth rates, reduce embryo waste, and lower the risk of miscarriage.

Dr. Chi-Hong Liu, the Chief Medical Advisor at NUWA Fertility and convener of the forum, emphasized that PGT-A can only deliver meaningful results when the platform is backed by solid evidence and high diagnostic accuracy. He noted that many currently used platforms lack sufficient clinical validation when it comes to identifying mosaic embryos. “Many embryos classified as mosaic still have the potential to implant and result in healthy live births,” said Dr. Liu. “If we discard them based on imprecise technology, we’re not only limiting patients’ chances but possibly wasting embryos with real potential.”

AI-Powered Embryo Selection: Precision without Harm

Mr. Takahashi, a senior embryologist from Japan’s renowned Kato Ladies Clinic, shared advancements in embryo assessment using AI combined with time-lapse imaging technology. This non-invasive method continuously monitors embryo development and uses algorithmic scoring to improve selection accuracy – particularly useful for patients with a limited number of eggs or who should avoid repeated ovarian stimulation. The approach has significantly improved success rates for single embryo transfer, a strategy aimed at reducing the risks of multiple pregnancies.

Behind Every IVF Success: A Seamless Teamwork Between Lab and Clinic

Dr. Shang-Gwo Horng, the Director of NUWA Fertility Center, offered clinical strategies for gentle yet effective ovarian stimulation and medication protocols that support embryo quality. And Dr. Chung-Hao Lu, a leading researcher and embryologist, discussed best practices for helping patients improve embryo outcomes through lifestyle and treatment. He emphasized that even the best PGT-A platform can fail if the biopsy timing, technique, or sample handling are subpar. “Close coordination between physicians and embryologists is absolutely essential to maximize IVF success,” said Dr. Lu.

NUWA Forum: Advancing Fertility Through Evidence-Based Collaboration

Dr. Chi-Hong Liu concluded by reaffirming NUWA’s mission to drive innovation through open knowledge-sharing and scientific rigor. “By building a better-validated, more reliable PGT-A platform, we can help patients increase their chances of success while reducing unnecessary stress and resource loss.”

Now in its third consecutive year, NUWA Fertility’s Reproductive Medical Forum continues to be a vital platform for pushing boundaries in fertility care. Dr. Liu added that NUWA will remain committed to integrating clinical decision-making, lab excellence, and global collaboration to elevate Taiwan’s reproductive medicine on the international stage.

Get to know NUWA: https://www.nuwacare.com/en

TOKYO, Aug. 6, 2025 /PRNewswire/ — Japan’s workforce is undergoing slow but significant transformation, even as it ranks the lowest across Asia-Pacific in ambition, mobility, and values-driven employment decisions. A newly released white paper by recruitment firm Reeracoen and research agency Rakuten Insight Global highlights how cultural norms around stability and tradition are giving way to quiet shifts in upskilling and flexibility.

The Reeracoen × Rakuten Insight APAC Workforce Whitepaper 2025, which surveyed over 12,000 professionals across 12 Asia-Pacific markets, reveals that Japan trails the region in several key workforce indicators. Only 24% of Japanese respondents strongly aspire to leadership roles, only 48% say ESG factors influence their employment decisions, and hybrid work adoption remains low at 33%.

“This report highlights a pivotal truth: the future of work in Japan depends on how well businesses can balance tradition with change,” said Kenji Naito, Group CEO of Reeracoen. “While the data shows Japan ranks lowest in ambition, mobility, and ESG alignment, it also reveals an opportunity. Organisations that respond to these shifts through flexibility, purpose, and skills development will lead the next chapter of Japan’s growth.”

Key Findings from Japan:

• Conservative Career Ambitions: Only 24% of Japanese workers strongly aspire to leadership roles, well below the APAC average of 37%.
• Limited ESG Influence: Only 48% of respondents evaluate CSR or ESG commitments when choosing an employer. This is the lowest score in the region.
• Slow Progress on Flexibility: While 65% of respondents say flexibility is important, only 33% currently have access to a hybrid work arrangement.
• Reluctance to Relocate: Japan has the lowest rates of openness to relocation, with only 9% of respondents open to moving overseas for work.
• Upskilling Gathers Momentum: There are encouraging signs that Japanese workers are taking more ownership over their career development. One in three workers (33%) are now pursuing skills development independently, primarily through certifications and online platforms.
• Conservative Salary Expectations: Only 13% expect a pay rise of more than 10% this year, compared to 21% regionally.

As Japan’s demographic challenges intensify and global competition for skilled talent increases, the need to adapt is becoming more urgent. Lifetime employment and seniority remain strong anchors; however, the data suggests that quiet and meaningful changes in areas such as hybrid work and digital learning are already underway. Employers that enhance their policies around flexibility, ESG, and upskilling will be better positioned to attract younger, more globally minded professionals.

“Japan’s labour market is quietly but steadily evolving,” said Kosuke Soejima, Managing Director of Reeracoen Japan. “As global trends accelerate, our clients are recognising that attracting and retaining talent requires more than stability. It demands purpose, trust, and flexible, human-centric work models.”

About the Study

 The whitepaper synthesises insights from over 12,000 respondents across the APAC region, including Japan. It provides both regional analysis and market-specific breakdowns to support workforce benchmarking and strategic planning.

About Reeracoen

Reeracoen is an award-winning leader in Asia’s recruitment landscape, connecting top-tier talent with forward-thinking organisations across the region. With nine offices across six major Asian countries, we combine deep local networks with cross-border hiring expertise to help businesses grow faster and stronger.

Our excellence has been recognised with recent awards such as:

• Best Recruitment & Talent Acquisition Agency 2025
• Best International Recruitment & Talent Acquisition Agency 2024
• Best Executive Recruitment Agency 2024

We uphold the highest standards of professionalism and service quality, providing innovative and trusted recruitment solutions to help businesses and candidates succeed in an evolving digital economy. For more information, visit https://www.reeracoen.sg and follow us on LinkedIn for the latest updates and insights.

About Rakuten Insight Global, Inc.

Rakuten Insight Global, Inc. (“Rakuten Insight”) is a wholly-owned online market research subsidiary of Rakuten Group, Inc., a global leader in internet services, headquartered in Tokyo. Rakuten Insight was established in 1997 as AIP Corporation and became part of the Rakuten Group in 2014. Rakuten Insight possesses a research panel focusing on 12 major Asian markets & the US and a panel network covering 60 countries and regions. With offices in 11 countries and regions, Rakuten Insight provides market research for over 500 leading companies around the world. Rakuten Insight Singapore serves as an off-shore market research hub to drive business development and provide multi-lingual and multi-functional operational support for clients based across Southeast Asia. For more information, visit https://insight.rakuten.com/  and follow us on social media.

GALWAY, Ireland, Aug. 6, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025, for its first quarter of fiscal year 2026, which ended on Friday, July 25, 2025,

• A news release containing summary financial information will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com
• A video webcast to discuss results will begin at 7:00 a.m. CDT and can be accessed at https://investorrelations.medtronic.com
• Within 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investorrelations.medtronic.com.

Looking ahead, Medtronic plans to report its fiscal year 2026 second, third, and fourth quarter results on Tuesday, November 18, 2025, February 17, 2026, and Wednesday, May 20, 2026, respectively. Confirmation and additional details will be provided closer to the specific event.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Erika Winkels
Public Relations
+1-763-526-8478

Ryan Weispfenning
Investor Relations
+1-763-505-4626

SYDNEY, Aug. 6, 2025 /PRNewswire/ — A revolutionary new brain health assessment platform, ScreenIT, has officially launched, marking a major step forward in how brain function is monitored, assessed, and optimised across sport, healthcare, and research sectors. Developed through a close partnership between Your Brain Health (YBH) and digital innovation studio Miroma Project Factory, ScreenIT unifies over 50 brain health assessment tools into a single, intelligent platform designed to support faster, more informed decision-making around concussion, performance, and long-term brain care.

Miroma Project Factory, specialists in creating high-impact digital solutions for health, consumer, broadcast and government sectors, collaborated with YBH’s visionary team, led by CEO Gregory Rosenbauer who states:

 “ScreenIT is more than an assessment tool – it’s an intelligent ecosystem that empowers clinicians, athletes, researchers, and communities to make better decisions, faster (about your brain health). From concept to launch, this has been a true collaboration driven by innovation, care, and a shared mission to foster healthier brains “

ScreenIT addresses a major gap in the market. Historically, brain health assessments have been fragmented and inconsistent. ScreenIT changes that by offering an integrated, real-time picture of brain function, pulling from a library of validated technologies and assessments. From elite athletes in the top-tier UK football competitions and Formula 1 to community clinics and research labs, ScreenIT delivers actionable insights when and where they’re needed most.

“Because every brain deserves better decisions, faster care and a healthier future. With Miroma Project Factory’s expertise, we’ve been able to realise a vision for a platform that not only improves concussion management but opens new pathways in talent identification, performance optimisation, and neurological research. Together, we’re building the foundation for a global brain health ecosystem to transform a bold idea into a globally scalable platform set to redefine brain health management.” said Gregory Rosenbauer, CEO and Co-Founder of Your Brain Health.

Backed by leaders in global sports medicine, including Professor Jon Patricios, founder of Sports Concussion South Africa and consultant to World Rugby, and Professor Mike Loosemore, former Chief Medical Officer of the UK Olympic Team, ScreenIT is positioned to become the gold standard in brain health technology.

Prof. Mike Loosemore MBE said, “Brain health is one of the most important yet overlooked frontiers in medicine. ScreenIT represents an opportunity to change that. By making brain function measurable, trackable and actionable, clinicians, athletes, and researchers are able to make better decisions that lead to healthier brains and better lives.”

ScreenIT is now available for selected partners and is being rapidly adopted across major sporting organisations and research institutions, with future plans including:

• Building a globally significant brain health data lake
• Integrating AI-driven predictive and personalised brain insights
• Achieving regulatory approval as the first-ever diagnostic tool for concussion and brain health management

Availability and Use

ScreenIT is now available for clinics within Australia and the UK market. Learn more about Your Brain Health and the ScreenIT platform here:

Your Brain Health: Fostering A World Of Healthier Brains

About Miroma Project Factory

Miroma Project Factory is a multi-award-winning digital production and development house specializing in creating innovative, interactive digital products across web, mobile, social media, and games platforms. With a deep expertise in health tech, sports tech, and gamification for behavior change, Miroma Project Factory partners with visionaries to bring impactful ideas to life. Visit https://www.theprojectfactory.com/ for more information.

To learn more about the creation of ScreenIT, explore our interview with Gregory Rosenbauer, CEO and Co‑Founder of Your Brain Health, in the Tech Founder Interview Series. For further details about the platform, visit the MPF ScreenIT case study https://www.theprojectfactory.com/projects/ybh 

About Your Brain Health (YBH)

Your Brain Health is a medical health and biotech company dedicated to improving brain health outcomes through innovative technology, education, and data-driven solutions. Led by a team of experts across sports medicine, neuroscience, and digital health, YBH’s mission is to foster a world of healthier brains through smarter care and faster decisions. 

For media inquiries, interviews, or partnership opportunities, please contact:

Miroma Project Factory
info@theprojectfactory.com

Gregory Rosenbauer
Chief Executive Officer
Your Brain Health
+61 4 1788 9263
greg.rosenbauer@yourbrainhealth.io

Available worldwide with real-time performance, low cost, and local support in Saudi Arabia

PALO ALTO, Calif. and RIYADH, Saudi Arabia, Aug. 6, 2025 /PRNewswire/ — Groq, the pioneer in fast inference, and HUMAIN, a PIF company and Saudi Arabia’s leading AI services provider, today announced the immediate availability of OpenAI’s two open models on GroqCloud. The launch delivers gpt-oss-120B and gpt-oss-20B with full 128K context, real-time responses, and integrated server-side tools live on Groq’s optimized inference platform from day zero.

Groq is the AI inference platform designed so customers can build fast, with the unmatched capacity and low cost to scale.

Groq has long supported OpenAI’s open-source efforts, including large-scale deployment of Whisper. This launch builds on that foundation, bringing their newest models to production with global access and local support through HUMAIN.

“OpenAI is setting a new high performance standard in open source models,” said Jonathan Ross, CEO of Groq. “Groq was built to run models like this, fast and affordably, so developers everywhere can use them from day zero. Working with HUMAIN strengthens local access and support in the Kingdom of Saudi Arabia, empowering developers in the region to build smarter and faster.”

“Groq delivers the unmatched inference speed, scalability, and cost-efficiency we need to bring cutting-edge AI to the Kingdom,” said Tareq Amin, CEO at HUMAIN. “Together, we’re enabling a new wave of Saudi innovation—powered by the best open-source models and the infrastructure to scale them globally. We’re proud to support OpenAI’s leadership in open-source AI.”

Built for full model capabilities

To make the most of OpenAI’s new models, Groq delivers extended context and built-in tools like code execution and web search. Web search helps provide real-time relevant information, while code execution enables reasoning and complex workflows. Groq’s platform delivers these capabilities from day zero with a full 128k token context length.

Unmatched price-performance

Groq’s purpose-built stack delivers the lowest cost per token for OpenAI’s new models while maintaining speed and accuracy.

gpt-oss-120B is currently running at 500+ t/s and gpt-oss-20B is currently running at 1000+ t/s on GroqCloud.

Groq is offering OpenAI’s latest open models at the following pricing:

• gpt-oss-120B: $0.15 / M input tokens and $0.75 / M output tokens
• gpt-oss-20B: $0.10 / M input tokens and $0.50 / M output tokens

Note: For a limited time, tool calls used with OpenAI’s open models will not be charged. Learn more at groq.com/pricing.

Global from day zero

Groq’s global data center footprint across North America, Europe, and the Middle East ensures reliable, high-performance AI inference wherever developers operate. Through GroqCloud, OpenAI’s open models are now available worldwide with minimal latency.

About Groq

Groq is the AI inference platform redefining price performance. Its custom-built LPU and cloud have been specifically designed to run powerful models instantly, reliably, and at the lowest cost per token—without compromise. Over 1.9 million developers trust Groq to build fast and scale smarter.

Contact: pr-media@groq.com

About HUMAIN

HUMAIN, a PIF company, is a global artificial intelligence company delivering full-stack AI capabilities across four core areas – next-generation data centers, hyper-performance infrastructure & cloud platforms, advanced AI Models, including the world’s most advanced Arabic multimodal LLMs, and transformative AI Solutions that combine deep sector insight with real-world execution.

HUMAIN’s end-to-end model serves both public and private sector organisations, unlocking exponential value across all industries, driving transformation and strengthening capabilities through human-AI synergies. With a growing portfolio of sector-specific AI products and a core mission to drive IP leadership and talent supremacy world-wide, HUMAIN is engineered for global competitiveness and national distinction.

www.humain.ai